Recent months have been marked with promising advances in the fight against liver cancers for patients around the globe. With the 5-year relative survival rate still at 20%, we still have a long way to go, but there is movement and hope. Be sure to stay abreast of the updates and please share your updates with us.
Ysabel Duron appointed to the National Cancer Advisory Board
We applaud Ysabel Duron, Founder and Executive Director of The Latino Cancer Institute, for being appointed to the National Cancer Advisory Board which compliments the Cancer Moonshot initiative. Ysabel is a nationally recognized and influential patient advocate leader who is dedicated to building community knowledge and capacity to respond to the cancer challenge, while amplifying Latino voices around issues of cancer. Ysabel was also a noteworthy roundtable guest for GLIs Hispanic and LatinX Health Equity Roundtable during the 2022 #OctoberIs4Livers campaign.
Exciting Phase III Results for Early-Stage HCC Treatment
It was announced January 18, 2023 that Genentech’s Tecentriq Plus Avastin is the first treatment combination found to reduce the risk of cancer returning in people with early-stage hepatocellular carcinoma (HCC) in a phase III trial. The study evaluated Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma at high risk of disease recurrence. The Tecentriq combination showed a statistically significant improvement in RFS in the intention-to-treat population of HCC patients who have an increased risk of recurrence following resection or ablation with curative intent, compared with active surveillance.
“Global Liver Institute is thrilled – Genentech, congrats! This is such positive news for the cancer community,” stated Sarah Manes, Liver Cancers Program Director at Global Liver Institute, “and we look forward to seeing the impact this has on the patients we advocate for.”
HCC-TAG Conference to Convene the Community February 23-25
GLI will be at HCC-TAG this year! The 2023 conference will bring together clinicians and researchers in academia and the pharmaceutical industry for a focused educational update to highlight the most relevant advances and challenges in the diagnosis and therapy of HCC. If you plan on attending, please contact GLIs Liver Cancers Program Director Sarah Manes at smanes@globalliver.org, and she would love to meet with you!
Building Liver Health Resilience in Cameroon
GLI celebrated #WorldCancerDay on February 4, 2023. Perfect timing for us to call out a must-see GLI LIVE video!! In this episode of GLI LIVE, Donna Cryer, GLI founder, CEO, and host of the show, talks with Mbianke Livancliff, MD, MPH, an NCD researcher and Bosch Fellowship alumnus who works with Value Health Africa and leads Empower Women Foundation. Dr. Livancliff discusses his ongoing advocacy work, particularly the fabulously successful open house held in partnership with Empower Women Foundation at Limbe Regional Hospital during the #OctoberIs4Livers campaign.
For more information about the Liver Cancers Council or to learn more about joining, please visit https://globalliver.org/liver-cancers-council/ or email cancer@globalliver.org.